Alice Pellegrini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alice Pellegrini has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Sibilio
UOC - Chirurgia Senologica Forlì-Ravenna, Ravenna (RA), Italy
1 shared publication - Donatella Santini
Pathology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy
1 shared publication Ghignone F
Department of Woman, Child and Urological Diseases, Policlinico S.Orsola-Malpighi, University of Bologna, Italy
1 shared publicationMaddalena Rocchi
Breast Center, Policlinico S.Orsola-malpighi Hospital, Bologna, Italy
1 shared publication- Margherita Serra
Breast Surgery Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
1 shared publication - Mario Taffurelli
UOC di Chirurgia Generale e Della Mammella Policlinico di Sant'Orsola, Università di Bologna, Bologna, Italy
1 shared publication
Latest Publications
- Open Access
- 26 December 2018
- Published by Gavin Publishers in Journal of Surgery
- Vol. 9 (12)
Locoregional Control After Breast Conserving Treatment in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
1. Abstract In the last decade Neoadjuvant Chemotherapy (NAC) has become more common for patients with operable breast cancer. Greatest advantage of this approach is that it can increase the proportion of patients who can be treated with Breast Conserving Therapy (BCT). This is a retrospective study of a prospective database regarding 573 patients, consecutively treated with BCT and ALND, among these 84 were treated with NAC. Primary end-point of this study was to evaluate long-term outcomes of patients treated with BCT after NAC. Secondarily we evaluated same outcomes in populations with comparable initial clinical stage; more over factors affecting the risk of developing a Locoregional Recurernce (LRR) were investigated. Incidence rate registered for LRR was 1/100 person per year for patients treated with adjuvant chemotherapy, while it is doubled in the NAC-group with 2/100 person per year. Ipsilateral breast tumour recurrences’ incidence rate was 1 IBTR per 100 persons per year in the first group and twice as much in the NAC-group. When considering only patients initially staged cT2, there is no significant difference in terms of outcome at 5 and 10 years. NAC shows equivalent outcomes compared to BCT and adjuvant chemotherapy especially when our case-series is analyzed by presenting clinical tumor stage, leading to satisfactory locoregional outcomes without affecting overall survival of patients, thus increasing considerably the rates of patients eligible for conservative treatment. 2. Keywords: Breast Cancer; Conservative Treatment; Locoregional Recurrences; Neoadjuvant Chemotherapy
- 26 December 2018
- Published by Gavin Publishers in Journal of Surgery
- Vol. 9 (12)
Open AccessLocoregional Control After Breast Conserving Treatment in Patients Undergoing Neoadjuvant Chemotherapy for Breast Cancer
1. Abstract In the last decade Neoadjuvant Chemotherapy (NAC) has become more common for patients with operable breast cancer. Greatest advantage of this approach is that it can increase the proportion of patients who can be treated with Breast Conserving Therapy (BCT). This is a retrospective study of a prospective database regarding 573 patients, consecutively treated with BCT and ALND, among these 84 were treated with NAC. Primary end-point of this study was to evaluate long-term outcomes of patients treated with BCT after NAC. Secondarily we evaluated same outcomes in populations with comparable initial clinical stage; more over factors affecting the risk of developing a Locoregional Recurernce (LRR) were investigated. Incidence rate registered for LRR was 1/100 person per year for patients treated with adjuvant chemotherapy, while it is doubled in the NAC-group with 2/100 person per year. Ipsilateral breast tumour recurrences’ incidence rate was 1 IBTR per 100 persons per year in the first group and twice as much in the NAC-group. When considering only patients initially staged cT2, there is no significant difference in terms of outcome at 5 and 10 years. NAC shows equivalent outcomes compared to BCT and adjuvant chemotherapy especially when our case-series is analyzed by presenting clinical tumor stage, leading to satisfactory locoregional outcomes without affecting overall survival of patients, thus increasing considerably the rates of patients eligible for conservative treatment. 2. Keywords: Breast Cancer; Conservative Treatment; Locoregional Recurrences; Neoadjuvant Chemotherapy